发明名称 Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer
摘要 Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
申请公布号 US9623079(B2) 申请公布日期 2017.04.18
申请号 US201414769069 申请日期 2014.02.26
申请人 The Board of Trustees of the Leland Stanford Junior University 发明人 Willingham Stephen;Howard Maureen;Liu Jie;Majeti Ravindra;Prohaska Susan Sweeney;Volkmer Anne Kathrin;Volkmer Jens-Peter;Weissman Irving L.
分类号 A61K39/395;A61K38/16;A61K38/18;C07K16/28;A61K39/00 主分类号 A61K39/395
代理机构 Bozicevic, Field & Francis LLP 代理人 Sherwood Pamela J.;Gurley Kyle A.;Bozicevic, Field & Francis LLP
主权项 1. A method of treating a mammalian subject with cancer with a therapeutic dose of an anti-CD47 agent that blocks the interaction between CD47 and SIRPα, selected from: an antibody that binds to CD47; an antibody that binds to SIRPα; a soluble SIRPα-binding CD47 fragment; and a soluble CD47-binding SIRPα fragment or a combination thereof, for treatment of the cancer, the method comprising: (a) administering a sub-therapeutic dose of one of the anti-CD47 agents to the subject, wherein the sub-therapeutic dose is effective to increase production of reticulocytes; and (b) administering a therapeutically effective dose of at least one of the anti-CD47 agents to the subject, wherein step (b) is performed in a range from about 3 days to about 21 days after beginning step (a).
地址 Stanford CA US